Background Orbital cavernous venous malformations (OCVMs) are the most common primary orbital mass lesion and presenting symptoms are usually secondary to a mass effect. Surgical excision presents ...

RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.

View all available purchase options and get full access to this article.

Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 7.02%, which has investors questioning if this is right time ...

这篇综述系统梳理了脑 cavernous 血管畸形（CCMs）的诊疗进展，涵盖保守监测、显微手术切除（MRS）、立体定向放射外科（SRS）等现有策略，并探讨了β受体阻滞剂、Rho激酶（ROCK）抑制剂、超氧化物歧化酶（SOD）模拟物等靶向治疗的潜力。作者强调需根据病灶位置 ...

while Recursion has four candidates in phase 2 trials including REC-994 for cerebral cavernous malformation, REC-2282 for neurofibromatosis type 2, and REC-4881 for familial adenomatous polyposis.

uic.edu Background The hemodynamic evaluation of cerebral arteriovenous malformations (AVMs) using DSA has not been validated against ... A-Vt was defined as the difference between peak contrast ...

Arteriovenous malformations (AVMs) and intracranial aneurysms contribute to a high degree of morbidity and mortality due to the risk of intracranial hemorrhage observed in each of these ...

High-sensitivity C-reactive protein and risk of retinal artery occlusion and ischaemic stroke: a cross-cohort study ...